Skip to main content
SpringerLink
Log in
Book cover

Antimicrobial Drug Resistance pp 629–646Cite as

Chemotherapy and Drug Resistance in Schistosomiasis,Fascioliasis and Tapeworm Infections

  • Chapter

Part of the book series: Infectious Disease ((ID))

It is estimated that nearly 400 million humans are infected with trematode or cestode parasites (Table 1, (1)). Nearly half of the infections are caused by two species of schistosome (blood fl ukes), Schistosoma mansoni and S. haematobium and most of this chapter will therefore be concerned with these parasites, and praziquantel (PZQ), the principal drug being used against them. Brief mention will however also be made of other schistosomicidal drugs, treatment of infections caused by another trematode, the liver fl uke Fasciola hepatica, and treatment of cestode (tapeworm) infections.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Crompton DWT. How much helminthiasis is there in the world? J Parasitol 1999; 85:397–403

    Article  PubMed  CAS  Google Scholar 

  2. Mahmoud AAF. Schistosomiasis. Imperial College Press, London, 2001

    Book  Google Scholar 

  3. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop 2000; 77:41–51

    Article  PubMed  CAS  Google Scholar 

  4. Engels D, Chitsulo L, Montresor A, Savioli L. The global epidemic of schistosomiasis and new approaches to control. Acta Trop 2002; 82:139–146

    Article  PubMed  CAS  Google Scholar 

  5. Whitty CJM, Mabey DC, Armstrong M, Wright SG, Chiodini PL. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans R Soc Trop Med Hyg 2000; 94:531–534

    Article  PubMed  CAS  Google Scholar 

  6. McKerrow JH, Salter J. Invasion of skin by schistosome cercariae. Trends Parasitol 2002; 18:193–195

    Article  PubMed  Google Scholar 

  7. Curwen RS, Wilson RA. Invasion of skin by schistosome cercariae: some neglected facts. Trends Parasitol 2003; 19:63–66

    Article  PubMed  Google Scholar 

  8. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford, 1992

    Google Scholar 

  9. Van der Werf MJ, de Vlas SJ, Brooker S, et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003; 86:125–139

    Article  PubMed  Google Scholar 

  10. Proudman CJ, French NJ, Trees AJ. Tapeworm infection is a significant risk factor for spastic colic and ileal impaction colic in the horse. Equine Vet 1998; 30:194–199

    Article  CAS  Google Scholar 

  11. Elliott DCV. Tapeworm (Moniezia expansa) and its effect on sheep production: the evidence reviewed. N Z Vet J 1986; 34:61–65

    PubMed  CAS  Google Scholar 

  12. Carpio A. Neurocysticercosis: an update. Lancet Infect Dis 2002; 2:751–762

    Article  PubMed  Google Scholar 

  13. Garcia HH, Gonzalez AE, Evans CA, Gilman RH. Cysticercosis Group in Peru. Taenia solium cysticercosis. Lancet 2003; 362: 547–556

    Article  PubMed  Google Scholar 

  14. Hagan P, Appleton CC, Coles GC, Kusel JR, Tchuem-Tchuente LA. Schistosomiasis control: keep taking the tablets. Trends Parasitol 2004; 20:92–97

    Article  PubMed  CAS  Google Scholar 

  15. Fenwick A, Savioli L, Engels D, Bergquist NR, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 2003; 19:509–515

    Article  PubMed  CAS  Google Scholar 

  16. Cioli D, Pica-Mattoccia L, Archer S. Antischistosomal drugs: past, present…and future? Pharmacol Ther 1995; 68:35–85

    Article  PubMed  CAS  Google Scholar 

  17. Cioli D. Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis 2000; 13:659–663

    PubMed  CAS  Google Scholar 

  18. Doenhoff MJ, Kusel JR, Coles GC, Cioli D. Resistance of Schistosoma mansoni to praziquantel: is there a problem. Trans R Soc Trop Med Hyg 2002; 96:465–469

    Article  PubMed  CAS  Google Scholar 

  19. Cioli D, Pica-Mattoccia L. Praziquantel. Parasitol Res 2003; 90:S3–S9

    PubMed  Google Scholar 

  20. Doenhoff MJ, Francklow K. Schistosome drug resistance: prazi-quantel. In: Gillespie SH, ed. Multiple Drug Resistant Infections. Humana Press Inc, Totowa, NJ. 2003; 341–352

    Google Scholar 

  21. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Inf Dis 2008; 21:659–667

    Article  CAS  Google Scholar 

  22. Engels D, Chitsulo L, Montresor A, Savioli L. The global epidemic of schistosomiasis and new approaches to control. Acta Trop 2002; 82:139–146

    Article  PubMed  CAS  Google Scholar 

  23. Crompton DWT, Engels D, Montresor A, Neira MP, Savioli L. Action starts now to control disease due to schistosomiasis and soil-transmitted helminthiasis. Acta Trop 2003; 86:121–124

    Article  PubMed  CAS  Google Scholar 

  24. Utzinger J, Bergquist R, Shu-Hua X, Singer B, Tanner M. Sustainable schistosomiasis control — the way forward. Lancet 2003; 362:1932–1934

    Article  PubMed  Google Scholar 

  25. Utzinger J, Kaiser J. Schistosomiasis and soil-transmitted helmin-thiasis: common drugs for treatment and control. Expert Opin Pharmacother 2004; 5:263–285

    Article  PubMed  CAS  Google Scholar 

  26. Groll E. Praziquantel. Adv Pharmacol Chemother 1984; 20: 219–238

    Article  PubMed  CAS  Google Scholar 

  27. Seubert J, Pohlke R, Loebich F. Synthesis and properties of praziqu-antel, a novel broad spectrum anthelminthic with excellent against schistosomes and cestodes. Experientia 1977; 33:1036–1037

    Article  PubMed  CAS  Google Scholar 

  28. Gönnert R, Andrews P. Praziquantel, a new broad-spectrum anti-schistosomal agent. Zeit Parasitenk 1977; 52:129–150

    Article  Google Scholar 

  29. Katz N, Rocha R, Chaves A. Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. Bull WHO 1979; 57:781–785

    PubMed  CAS  Google Scholar 

  30. Davis A, Biles JE, Ulrich A-M. Initial experiences with prazi-quantel in the treatment of human infections due to Schistosoma haematobium. Bull WHO 1979; 57:773–779

    PubMed  CAS  Google Scholar 

  31. Ishizaki T, Kamo E, Boehme K. Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections. Bull WHO 1979; 57:787–791

    PubMed  CAS  Google Scholar 

  32. Andrews P, Thomas H, Pohlke R, Seubert J. Praziquantel. Med Res Rev 1983; 3:147–200

    Article  PubMed  CAS  Google Scholar 

  33. Liu YH, Wang QN, Wang XG, Zhan QD, Lu XE, Jian YF, Wang RQ, Yan SW, Che BY, Li JS, Qiu ZY, Shen JK. Comparative efficacy of praziquantel and its optic isomers in experimental therapy of schistosomiasis japonica in rabbits China Med J 1986; 99:935–940

    CAS  Google Scholar 

  34. Wu MH, Wei CC, Xu ZY, Yuan HC, Lian WN, Yang QJ, Chen M, Jiang QW, Wang CZ, Zhang SJ. Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isome praziquantel in 278 cases of schistosomiasis japonica. Am J Trop Med Hyg 1991; 45:345–349

    PubMed  CAS  Google Scholar 

  35. Doenhoff MJ, Kimani G, Cioli D. Praziquantel and the control of schistosomiasis. Parasitol Today 2000; 16:364–366

    Article  PubMed  CAS  Google Scholar 

  36. Appleton CC, Mbaye A. Praziquantel — quality, dosages and markers of resistance. Trends Parasitol 2001; 17:356–357

    Article  PubMed  CAS  Google Scholar 

  37. Sulaiman SM, Traoré M, Engels D, Hagan P, Cioli D. Counterfeit praziquantel. Lancet 2001; 358:666–667

    Article  PubMed  CAS  Google Scholar 

  38. World Health Organization. Prevention and control of schisto-somiasis and soil-transmitted helminthiasiss. Report of a WHO Expert Committee. WHO Technical Report Series 912. WHO, Geneva. 2002

    Google Scholar 

  39. Castro N, Medina R, Sotelo J, Jung H. Bioavailability of praziquan-tel increases with concomitant administration of food. Antimicrob Agents Chemother 2000; 44:2903–2904

    Article  PubMed  CAS  Google Scholar 

  40. Valencia CI, Catto BA, Webster LT Jr, Barcelon E, Ofendo-Reyes R. Concentration time course of praziquantel in Filipinos with mild Schistosoma japonicum infection. Southeast Asian J Trop Med Public Health 1994; 25:409–414

    PubMed  CAS  Google Scholar 

  41. Leopold G, Ungethum W, Groll E, Diekman HW, Nowak H, Wegner DH. Clinical pharmacology in normal volunteers of prazi-quantel, a new drug against schistosome and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol 1978; 14:281–291

    Article  PubMed  CAS  Google Scholar 

  42. Mandour ME, El Turabi H, Homeida MM, El Sadig T, Ali HM, Bennett JL, Leahey WJ, Harron DW. Pharmacokinetics of praziqu-antel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg 1990; 84:389–393

    Article  PubMed  CAS  Google Scholar 

  43. Webbe G, James C. A comparison of the susceptibility to prazi-quantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum, and S. mattheei in hamsters. Zeit Parasitenkd 1977; 52:169–177

    Article  CAS  Google Scholar 

  44. Wegner DHG. The profile of the trematocidal compound praziqu-antel. Arzneimittelforschung 1984; 34:1132–1136

    PubMed  CAS  Google Scholar 

  45. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma man-soni: chemotherapy of infections of different ages. Exp Parasitol 1986; 61:294–303

    Article  PubMed  CAS  Google Scholar 

  46. Xiao SH, Catto BA, Webster LT. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 1985; 151:1130–1137

    PubMed  CAS  Google Scholar 

  47. Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol 2004; 34:527–533

    Article  PubMed  CAS  Google Scholar 

  48. Renganathan E, Cioli D. An international initiative on praziquantel use. Parasitol Today 1998; 14:390–391

    Article  PubMed  CAS  Google Scholar 

  49. Piquet M, Vercruysse J, Shaw DJ, Diop M, Ly A. Efficacy of prazi-quantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg 1998; 92:90–93

    Article  Google Scholar 

  50. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 2000; 5:771–778

    Article  PubMed  CAS  Google Scholar 

  51. Coles GC, Hillyer MH, Taylor FGR, Villard I. Efficacy of an ivermectin-praziquantel combination in equids. Vet Rec 2003; 152:178–179

    PubMed  CAS  Google Scholar 

  52. Mason P, Moffat J, Cole D. Tapeworm in sheep revisited. Proceedings of the 32nd Seminar of the Society of Sheep and Beef Cattle Veterinarians New Zealand Veterinary Association, Wellington 22–24 May 2002. pp. 147–151

    Google Scholar 

  53. Becker B, Melhorn H, Andrews P, Thomas H, Eckert J. (1980) Light and electron microscope studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Zeit Parasitenkd 1980; 63:113–128

    Article  CAS  Google Scholar 

  54. Knobloch J, Delgado E, Alvarez A, Reymann U, Bialek R. Human fasciolosis in Cajamarca/Peru. I Diagnostic method: and treatment with praziquantel. Trop Med Parasitol 1985; 36:88–90

    PubMed  CAS  Google Scholar 

  55. Farag HF, Ragab M, Salem A, Sadek N. A short note on praziqu-antel in human fasciolosis. J Trop Med Hyg 1986; 89:79–80

    PubMed  CAS  Google Scholar 

  56. Ishii Y, Nakamura-Uchiyama F Nawa Y. A praziquantel-ineffective fascioliasis case successfully treated with triclabendazole. Parasitol Int 2002; 51:205–209

    Article  PubMed  Google Scholar 

  57. Moreau JA, Fernandez J, Recco P, Seguela JP, Rexinos J. Efficacy and tolerance of praziquantel (Biltricide) in the treatment of disto-matosis caused by Fasciola hepatica. Gastoenterol Clin Biol 1995; 19:514–519

    CAS  Google Scholar 

  58. Atalay F, Kirimlioglu V, Dagli U, Akincioglu T, Akoglu M, Seven C. Human fasciolosis. Surg Today 1993; 23:366–369

    Article  PubMed  CAS  Google Scholar 

  59. Steiner K, Garbe A, Diekerman HW, Novak H. The fate of praziqu-antel in the organism. I: pharmacokinetics in animals. Eur J Drug Metab Pharmacokinet 1976; 1:85–95

    Article  CAS  Google Scholar 

  60. Masimermbwa CM, Hasler JA. Characterization of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem Pharmacol 1994; 48; 1779–1783

    Article  Google Scholar 

  61. Riditidid W, Wongwana M, Mahatthanatrakul W, Punyo J, Sunbhanich M. Rifampicin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther 2002; 72:505–513

    Article  CAS  Google Scholar 

  62. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome p(450)s that metabolize anti-parasitic drugs and predictons of in vivo hepatic clearance from in vitro data. Eur J Clin Pharmacol 2003; 59:429–442

    Article  PubMed  CAS  Google Scholar 

  63. Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother 1997; 41:1256–1259

    PubMed  CAS  Google Scholar 

  64. El Guiniady MA, El Touney MA, Abdel-Bary MA, Abdel-Fatah SA, Metwally A. Clinical and pharmacokinetic study of praziquan-tel in Egyptian schistosomiasis patients with and without liver cell failure. Am J Trop Med Hyg 1994; 51:809–818

    PubMed  CAS  Google Scholar 

  65. Frohberg H. Results of toxicological studies on praziquantel. Arzneimittelforschung 1984; 34:1137–1144

    PubMed  CAS  Google Scholar 

  66. Kramers PGN, Gentile JM, Gryessles BJM, Jordan P, Katz N, Mott KE, Mulvihill JJ, Seed JL, Frohberg H. Review of the genotoxicity and carcinogenicity of antischistosomal drugs: is the a case for a study of mutation epidemiology? Report of a task group on muta-genic antischistosomals. Mutation Res 1991; 257:49–89

    PubMed  CAS  Google Scholar 

  67. Montero R, Ostrosky P. Genotoxic activity of praziquantel. Mutation Res 1997; 387:123–139

    Article  PubMed  CAS  Google Scholar 

  68. Bassily S, Farid Z, Dunn M, El-Masry NA, Stek M Jr Praziquatel for treatment of schistosomiasis in patients with advanced splenomegaly. Ann Trop Med Parasitol 1985; 79:629–634

    PubMed  CAS  Google Scholar 

  69. Allen HE, Crompton DW, De Silva N, LoVerde PT, Olds GR. New policies for using anthelmintics in high risk groups. Trends Parasitol 2002; 18:381–382

    Article  PubMed  Google Scholar 

  70. Jaoko WG, Muchemi G, Castro N, Corona T, Sotelo J. Praziquantel side effects during treatment of Schistosomama mansoni infected pupils in Kibwezi, Kenya. East Afr Med J 1996; 73:499–501

    PubMed  CAS  Google Scholar 

  71. Berhe N, Gundersen SG, Abebe F, Birrie H, Medhin G, Gemetchu T. Praziquantel side effects and efficacy related to Schistosoma man-soni egg loads and morbidity in primary school children in northeast Ethiopia. Acta Trop 1999; 72:53–63

    Article  PubMed  CAS  Google Scholar 

  72. Polderman AM, Gryseels B, Gerold JL, Mpamila K, Manshande JP. Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire. Trans R Soc Trop Med Hyg 1984; 78:752–754

    Article  PubMed  CAS  Google Scholar 

  73. Pax R, Bennett JL, Fetterer R. A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schiedbergs Arch Pharmacol 1978; 304:309–315

    Article  CAS  Google Scholar 

  74. Nechay BR, Hillman GR, Dotson MJ. Properties and drug sensitivity of adenosine triphosphatases from Schistosoma mansoni. J Parasitol 1980; 66:596–600

    Article  PubMed  CAS  Google Scholar 

  75. Mehlhorn H, Becker B, Andrews P, Thomas H, Frenkel JK. In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. Drug Res 1981; 31:544–554

    CAS  Google Scholar 

  76. Harnet W, Kusel JR. Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquan-tel in vitro. Parasitology 1986; 93:401–405

    Article  Google Scholar 

  77. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni — reduced efficacy of chemotherapy in infected T-cell-deprived mice. Exp Parasitol 1985; 60:348–354

    Article  PubMed  CAS  Google Scholar 

  78. Brindley PJ, Sher A. The chemotherapeutic effect of praziquan-tel against Schistosoma mansoni is dependent on host antibody response. J Immunol 1987; 139:215–220

    PubMed  CAS  Google Scholar 

  79. Doenhoff MJ, Sabah AA, Fletcher C, Webbe G, Bain J. Evidence of an immune-dependent action of praziquantel on Schistosoma mansoni in mice. Trans R Soc Trop Med Hyg 1987:81:947–951

    Article  PubMed  CAS  Google Scholar 

  80. Doenhoff MJ, Modha J, Lambertucci JR. Anti-schistosome chemotherapy enhanced by antibodies specific for a parasite surface esterase. Immunology 1988; 65:507–510

    PubMed  CAS  Google Scholar 

  81. Brindley PJ, Strand M, Norden AP, Sher A. Role of host antibody in the chemotherapeutic action of praziquantel against Schistosoma mansoni: identification of target antigens. Mol Biochem Parasitol 1989; 334:99–108

    Article  Google Scholar 

  82. Karanja DHS, Boyer AE, Strand M, Colley DG, Nahlen BL, Ouma JH, Secor WE. Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency VIRUS-1. Am J Trop Med Hyg 1998; 59:307–311

    PubMed  CAS  Google Scholar 

  83. Bricker CS, Depenbusch JW, Bennett JL, Thompson DP. The relationship between tegumental disruption and muscle contraction in Schistosoma mansoni exposed to various compounds. Z Parasitenkd 1983; 69:61–71

    Article  PubMed  CAS  Google Scholar 

  84. Harder A, Goossens J, Andrews P. Influence of praziquantel and Ca2+ on the bilayer-isotropic-hexagonal transition of model membranes. Mol Biochem Parasitol 1988; 29:55–60

    Article  PubMed  CAS  Google Scholar 

  85. Schepers H, Brasseur R, Goormaghtigh E, Duquenoy P, Ruysschaert JM. Mode of insertion of praziquantel and derivatives into lipid membranes. Biochem Pharmacol 1988; 37:1615–1623

    Article  PubMed  CAS  Google Scholar 

  86. McTigue MA, Williams DR, Tainer JA. Crystal structures of a schistosomal drug and vaccine target: glutathione S-transferase from Schistosoma japonica and its complex with the leading antischistosomal drug praziquantel. J Mol Biol 1995; 246:21–27

    Article  PubMed  CAS  Google Scholar 

  87. Milhon JL, Thiboldeaux RL, Glowac K, Tracy JW. Schistosoma japonicum GSH S-transferase Sj26 is not the molecular target of praziquantel action. Exp Parasitol 1997; 87:268–274

    Article  PubMed  CAS  Google Scholar 

  88. Kohn AB, Anderson PA, Roberts-Misterly JM, Greenberg RM. Schistosome calcium channel beta subunits: unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J Biol Chem 2001; 276, 36873–36876

    Article  PubMed  CAS  Google Scholar 

  89. Kohn AB, Roberts-Misterly JM, Anderson PA, Greenberg RM. Creation by mutagenesis of a mammalian Ca(2+) channel beta subunit that confers praziquantel sensitivity to a mammalian Ca(2+) channel. Int J Parasitol 2003; 33:1303–1308

    Article  PubMed  CAS  Google Scholar 

  90. Kohn AB, Roberts-Misterly JM, Anderson PAV, Khan N, Greenberg RM. Specific sites in the beta interaction domain of a schisto-some Ca2+ channel beta subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel. Parasitology 2003; 127:349–356

    Article  PubMed  CAS  Google Scholar 

  91. Stelma FF, Talla I, Polman K, Niang M, Sturrock RF, Deelder AM, Gryseels B. Epidemiology of Schistosoma mansoni infection in a recently exposed community in Northern Senegal. Am J Trop Med Hyg 1993; 49:701–706

    PubMed  CAS  Google Scholar 

  92. Southgate VR. Schistosomiasis in the Senegal river basin: before and after the construction of the dams at Diama, Senegal and Manantali, Mali and future prospects. J Helminthol 1997; 71:125–132

    Article  PubMed  CAS  Google Scholar 

  93. Gryseels B, Stelma FF, Talla I, Van Dam GJ, Polman K, Sow S, Diaw M, Sturrock RF, Doehring-Scwerdtfeger E, Kardoff R, Decam C, Niang M, Deelder AM. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 1994; 46:209–219

    PubMed  CAS  Google Scholar 

  94. Stelma FF, Talla I, Sow S, Kongs A, Niang M, Polman K, Deelder AM, Gryseels B. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 1995; 53:167–170

    PubMed  CAS  Google Scholar 

  95. Guisse F, Polman K, Stelma FF, Mbaye A, Talla I, Niang M, Deelder AM, Ndir O, Gryseels B. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in northern Senegal. Am J Trop Med Hyg 1997; 56:511–514

    PubMed  CAS  Google Scholar 

  96. Tchuente LAT, Southgate VR, Mbaye A, Engels D, Gryseels B. The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal. Trans R Soc Trop Med Hyg 2001; 95:65–66

    Article  Google Scholar 

  97. Fallon PG, Capron A, Sturrock RF, Niang CM, Doenhoff MJ. Short report — diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg 1995; 53:61–62

    PubMed  CAS  Google Scholar 

  98. Fallon PG, Mubarak JS, Fookes RE, Niang M, Butterworth AE, Sturrock RF, Doenhoff MJ. Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates. Exp Parasitol 1997; 86:29–36

    Article  PubMed  CAS  Google Scholar 

  99. Liang Y-S, Coles GC, Doenhoff MJ, Southgate VR. In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int J Parasitol 2001; 31:1227–1235

    Article  PubMed  CAS  Google Scholar 

  100. Stelma FF, Sall S, Daff B, Sow S, Niang M, Gryseels B. Oxamniquine cures Schistosoma mansoni in a focus in which cure rates with praziquantel are unusually low. J Infect Dis 1997; 176:304–307

    Article  PubMed  CAS  Google Scholar 

  101. El Khoby T, Galal N, Fenwick A. The USAID government of Egypt's schistosomiasis research project (SRP). Parasitol Today 1998; 14:92–96

    Article  PubMed  CAS  Google Scholar 

  102. Ismail M, Metwally A, Farghally A, Bruce J, Tao LF, Bennett JL. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 1996; 55:214–218

    PubMed  CAS  Google Scholar 

  103. Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, Day TA, Bennett JL. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999; 60:932–935

    PubMed  CAS  Google Scholar 

  104. Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug-specific. Am J Trop Med Hyg 1994:51:83–88

    PubMed  CAS  Google Scholar 

  105. Cioli D, Botros SS, Wheatcroft-Francklow K, Mbaye A, Southgate V, Tchuem Tchuenté L-A, Pica-Mattoccia L, Troiani AR, Seif el-Din SH, Sabra A-NA, Albin J, Engels D Doenhoff MJ. Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int J Parasitol 2004; 34:979–987

    Article  PubMed  CAS  Google Scholar 

  106. Pereira C, Fallon PG, Cornette JC, Capron A, Doenhoff MJ, Pierce RJ. Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni. Parasitology 1998; 117:63–73

    Article  PubMed  CAS  Google Scholar 

  107. Tsai M-H, Marx KA, Ismail MM, Tao L-F. Randomly-amplified polymorphic DNA (RAPD) polymerase chain reaction assay for determination of Schistosoma mansoni strains sensitive or tolerant to anti-schistosomal drugs. J Parasitol 2000; 86:146–149

    PubMed  CAS  Google Scholar 

  108. Valle C, Troiani AR, Festucci A, Pica-Mattoccia L, Liberti P, Wolstenholme A, Francklow K, Doenhoff MJ, Cioli D. Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel. Mol Biochem Parasitol 2003; 130:111–115

    Article  PubMed  CAS  Google Scholar 

  109. William S, Botros S, Ismail M, Farghally A, Day TA, Bennett JL. Praziquantel-induced tegumental damage is diminished in schistosomes derived from praziquantel-resistant infections. Parasitology 2001; 122:63–66

    Article  PubMed  CAS  Google Scholar 

  110. Liang Y-S, Coles GC, Dai J-R, Zhu Y-C, Doenhoff MJ. Adult worm tegumental damage and egg-granulomas in praziquantel-resistant and -susceptible Schistosoma mansoni treated in vivo. J Helminthol 2002; 76:327–333

    Article  PubMed  Google Scholar 

  111. Gryseels B, Mbaye A, De Vlas SJ, Stelma FF, Guisse F, Van Lieshout L, Faye D, Diop M, Ly A, Tchuem-Tchuente LA, Engels D, Polman K. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 2001; 6:864–873

    Article  PubMed  CAS  Google Scholar 

  112. Dansio-Appiah A, De Vlas SJ. The interpretation of low praziqu-antel cure rates in population treatment of Schistosoma mansoni infection. Trends Parasitol 2002; 18:125–129

    Article  Google Scholar 

  113. Richards HC, Foster R. A new series of 2-aminomethyltetrahy-droquinolone derivatives displaying schistosomicidal activity in rodents and primates. Nature 1969; 222:581–582

    Article  PubMed  CAS  Google Scholar 

  114. Da Silva LC, Sette H Jr, Chamone DA, Alquezar AS, Punskas JA, Raia S. Clinical trials with oral oxamniquine (UK 4271) for the treatment of mansonian schistosomiasis. Rev Inst Med Trop Sao Paulo 1974; 16:103–109

    PubMed  Google Scholar 

  115. Pica-Mattoccia L, Cioli D, Archer S. Binding of oxamniquine to the DNA of schistosomes. Trans R Soc Trop Med Hyg 1989; 83:89–96

    Article  Google Scholar 

  116. Beck L, Favre TC, Pieri OS, Zani LC, Domas GG, Barbosa CS. Replacing oxamniquine by praziquantel against Schistosoma mansoni infection in a rural community from the sugar-cane zone of Northeast Brazil: an epidemiological follow-up. Mem Inst Oswaldo Cruz 2001; 96 Suppl:165–167

    Article  PubMed  CAS  Google Scholar 

  117. Katz N. Schistosomiasis control in Brazil. Mem Inst Oswaldo Cruz 1998; 93 Suppl:33–35

    PubMed  Google Scholar 

  118. Khayyal MT, Girgis NL, Henry W. (1969) Effectiveness of a single dose of hycanthone orally in experimental schistosomiasis in hamsters. Bull WHO; 40:963–965

    PubMed  CAS  Google Scholar 

  119. Cioli D, Knopf PM. A study of the mode of action of hycanthone against Schistosoma mansoni in vivo and in vitro. Am J Trop Med Hyg 1980; 29:220–226

    PubMed  CAS  Google Scholar 

  120. Archer S, Yarinsky A. Recent developments in the chemotherapy of schistosomiasis. In: Jucker E, ed. Progress in Drug Research. Birkhäuser Verlag, Basel. 1972; 11–66

    Google Scholar 

  121. Pica-Mattoccia L, Dias LCS, Moroni R, Cioli D. Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine-resistant strains are mutated in the same gene. Exp Parasitol 1993; 77:445–449

    Article  PubMed  CAS  Google Scholar 

  122. Coles GC, Mutahi WT, Kinoti GK, Bruce JI, Katz N. Tolerance of Kenyan Schistosoma mansoni to oxamniquine. Trans R Soc Trop Med Hyg 1987; 81:782–785

    Article  PubMed  CAS  Google Scholar 

  123. Pica Mattoccia L, Cioli D. Effect of hycanthone administered in vivo upon the incorporation of radioactive precursors into macro-molecules of Schistosoma mansoni. Mol Biochem Parasitol 1983; 8:99–107

    Article  PubMed  CAS  Google Scholar 

  124. Cioli D, Pica-Mattoccia L, Moroni R. Schistosoma mansoni: hycanthone/oxamniquine resistant is controlled by a single auto-somal recessive gene. Exp Parasitol 1992; 75:425–432

    Article  PubMed  CAS  Google Scholar 

  125. Pica-Mattoccia L, Archer S, Cioli D. Hycanthone resistance in schistosomes correlates with the lack of an enzymatic activity which produces the covalent binding of hycanthone to parasite macromolecules. Mol Biochem Parasitol 1992; 55:167–176

    Article  PubMed  CAS  Google Scholar 

  126. Pica-Mattoccia L, Novi A, Cioli D. The enzymatic basis for the lack of oxamniquine activity in Schistosoma haematobium. Parasitol Res 1997; 83:687–689

    Article  PubMed  CAS  Google Scholar 

  127. Cioli D, Pica-Mattoccia L, Rosenberg S, Archer S. Evidence for the mode of antischistosomal action of hycanthone. Life Sci 1985; 37:161–167

    Article  PubMed  CAS  Google Scholar 

  128. Le WJ, You JQ, Mei J Y. Chemotherapeutic effect of artesunate in experimental schistosomiasis. Acta Pharmaceut Sin 1983; 18:619–621 (in Chinese)

    CAS  Google Scholar 

  129. Xiao SH, Tanner M, N'Goran EK, Utzinger J, Chollet J, Bergquist R, Chen MG, Zheng J. Recent investigations of artemeter, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop 2002; 82; 175–181

    Article  PubMed  CAS  Google Scholar 

  130. Hu SY, Liu J, Wang B, Hu ZD, Xiao CJ. The effect of artesunat in protecting the populations from Schistosoma japonicum during flood control. China J Parasitol Parasit Dis 2000; 18:113–114

    CAS  Google Scholar 

  131. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Xiao SH, Tanner M. Oral artemeter for prevention of Schistosoma mansoni infection: randomized control trial. Lancet 2000; 355:1320–1325

    Article  PubMed  CAS  Google Scholar 

  132. N'Goran EK, Utzinger J, Gnaka HN, Yapi A, N'Guessan NA, Kigbafori SD, Lengeler C, Chollet J, Xiao SH. Randomized double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infection. Am J Trop Med Hyg 2003; 68:24–32

    PubMed  Google Scholar 

  133. Sulaiman SM, Ali HM, Homeida MM, Bennett JL. Efficacy of a new Hoffmann-La Roche compound (Ro 15-5458) against Schistosoma mansoni (Gezira strain, Sudan) in vervet monkeys (Cercopithecus aethiops). Trop Med Parasitol 1989; 40:335–336

    PubMed  CAS  Google Scholar 

  134. Sturrock RF, Bain J, Webbe G, Doenhoff MJ, Stohler H. Parasitological evaluation of curative and subcurative doses of 9-acridanone-hydrazone drugs against Schistosoma mansoni in baboons, and observations on changes in serum levels of anti-egg antibodies detected by ELISA. Trans R Soc Trop Med Hyg 1987; 81:188–192

    Article  PubMed  CAS  Google Scholar 

  135. Pereira LH, Coelho PM, Costa JO, de Mello RT. Activity of 9-acridanone-hydrazone drugs detected at the pre-postural phase, in the experimental schistosomiasis mansoni. Mem Inst Oswaldo Cruz 1995; 90:425–428

    PubMed  CAS  Google Scholar 

  136. Metwally A, Abdel Hadi A, Mikhail EG, Abou Shadi O, Sabry H, el-Nahal H. Study of the efficacy of the new antischistosomal drug 10-[2-(diethylamino)ethyl]-9-acridanone-(thiazolidin-2-ylidene) hydrazone against an Egyptian strain of S. mansoni in mice. Arzneimittelforschung 1997; 47:975–979

    PubMed  CAS  Google Scholar 

  137. Guirguis FR. Efficacy of praziquantel and Ro 15-5458, a 9- acridanone-hydrazone derivative, against Schistosoma haematobium. Arzneittelforschung 2003; 53:57–61

    CAS  Google Scholar 

  138. Kamel G, Metwally A, Guirguis F, Nessim NG, Noseir M. Effect of a combination of the new antischistosomal drug Ro 15-5458 and praziquantel on different strains of Schistosoma mansoni infected mice. Arzneittelforschung 2000; 50:391–394

    CAS  Google Scholar 

  139. Eshete F, Bennett JL. The apparent absorption kinetics of Ro 15-5458, a schistosomicidal drug. J Antimicrob Chemother 1990; 25:255–261

    Article  PubMed  CAS  Google Scholar 

  140. Eschete F, Bennett JL. Schistosoma mansoni: biochemical characteristics of the antischistosomal effects of Ro 15-5458. Exp Parasitol 1990; 71:69–80

    Article  Google Scholar 

  141. Eschete F, Bennett JL. The schistosomicidal compound Ro 15-5458 causes a reduction in RNA content of Schistosoma mansoni. Mol Biochem Parasitol 1991; 45:1–8

    Article  Google Scholar 

  142. Bickle QD, Sacko M, Vignali DA. Induction of immunity against Schistosoma mansoni by drug (Ro 11-3128)-terminated infections: analysis of surface antigen recognition. Parasite Immunol 1990; 12:569–586

    Article  PubMed  CAS  Google Scholar 

  143. Stohler HR. Ro 11-3128, a novel schistosomicidal compound. In: Siegenthaler W, Lüthy R, eds. Current Chemotherapy. American Society for Microbiology, Washington. 1978; 147–148

    Google Scholar 

  144. Baard AP, Sommers DK, Honiball PJ, Fourie ED, du Toit LE. Preliminary results in human schistosomiasis with Ro 11-3128. S Afr Med J 1979; 55:617–618

    PubMed  CAS  Google Scholar 

  145. O'Boyle CA, Lambe R, Darragh A. Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam. Eur J Clin Pharmacol 1985; 29:105–108

    Article  PubMed  Google Scholar 

  146. Hunkeler W, Möler H, Pieri L, Pole P, Bonetti EP, Cumin R, Schaffner R, Haefely W. Selective antagonists of benzodi-azepines. Nature 1981; 290:514–516

    Article  PubMed  CAS  Google Scholar 

  147. Pax R, Bennett JL, Fetterer R. A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schiedbergs Arch Pharmacol 1978; 304:309–315

    Article  CAS  Google Scholar 

  148. Bennett JL. (1980) Characteristics of antischistosomal benzodi-azepine binding sites in Schistosoma mansoni. J Parasitol 1980; 66:742–747

    Article  PubMed  CAS  Google Scholar 

  149. Noel F, Mendonca-Silva DL, Thibaut JP, Lopes DV. Characterization of two classes of benzodiazepine binding sites in Schistosoma mansoni. Parasitology 2007; 22:1–10

    Google Scholar 

  150. Badria F, Abou-Mohamed G, El-Mowafy A, Massoud A, Slama O. Mirazid: a new schistosomicidal drug. Pharm Biol 2001; 93:127–131

    Article  Google Scholar 

  151. Sheir Z, Nasr AA, Massoud A, Salama O, Badra GA, El-Shennawy H, Hassan N, Hammad SM. A safe, effective, herbal antischisto-somal therapy derived from myrrh. Am J Trop Med Hyg 2001, 65:700–704

    PubMed  CAS  Google Scholar 

  152. Botros S, William S, Ebeid F, Cioli D, Katz N, Day TA, Bennett JL. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am J Trop Med Hyg 2004; 71:206–210

    PubMed  Google Scholar 

  153. De Souza Dias LC, De Jesus Pedro R, Deberaldini ER. Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and/or hycanthone: resistance of Schistosoma mansoni to schistosomicidal agents. Trans R Soc Trop Med Hyg 1982; 76:652–659

    Article  PubMed  Google Scholar 

  154. Katz N, Rocha RS, de Souza CP, Coura Filho P, Bruce JI, Coles GC, Kinoti GK. Efficacy of alternating therapy with oxamniq-uine and praziquantel to treat Schistosoma mansoni in children following failure of first treatment. Am J Trop Med Hyg 1991; 44:509–512

    PubMed  CAS  Google Scholar 

  155. Martin PJ, Le Jambre LF, Claxton JH. The impact of refugia on the development of thiabendazole resistance in Haemonchus contortus. Int J Parasitol 1981; 11:35–41

    Article  PubMed  CAS  Google Scholar 

  156. Van Wyk JA. Refugia — overlooked as perhaps the most potent factor concerning development of anthelmintic resistance. Ondesterpoort J Vet Res 2001; 68:55–67

    Google Scholar 

  157. Coles GC. Sustainable use of anthelmintics in grazing animals. Vet Rec 2002; 151:165–169

    PubMed  CAS  Google Scholar 

  158. William S, Sabra A, Ramzy F, Mousa M, Demerdash Z, Bennett JL, Day TA, Botros S. Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to prazi-quantel. Int J Parasitol 2001; 31:1093–1100

    Article  PubMed  CAS  Google Scholar 

  159. Liang YS, Coles GC, Dai J-R, Zhu Y-C, Doenhoff MJ. (2001) Biological characteristics of praziquantel-resistant and - susceptible isolate of Schistosoma mansoni. Ann Trop Med Parasitol 2001; 95:715–723

    Article  PubMed  CAS  Google Scholar 

  160. Coles GC, Stafford KA. Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against adult triclabendazole-resistant Fasciola hepatica. Vet Rec 2001; 148: 723–724

    PubMed  CAS  Google Scholar 

  161. Coles GC, Rhodes AC, Stafford KA. The activity of closantel against adult triclabendazole-resistant Fasciola hepatica. Vet Rec 2000; 146:504

    PubMed  CAS  Google Scholar 

  162. Stitt AW, Fairweather I. Fasciola hepatica: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex). Parasitol Res 1993; 79:529–536

    Article  PubMed  CAS  Google Scholar 

  163. Stitt AW, Fairweather I. Spermatogenesis in Fasciola hepatica: an ultrastructrual comparison of the effects of the anthelmintic, tri-clabendzole (‘Fasinex’) and the microtubule inhibitor, tubulozole. Invert Reprod Develop 1992; 22:139–150

    CAS  Google Scholar 

  164. Faithweather I, Boray JC. Mechanisms of fasciolicide action and drug resistance in Fasciola hepatica. In: Dalton JP, ed. Fasciolosis. CABI International, Wallingford, 1999; 225–276

    Google Scholar 

  165. Stitt AW, Fairweather I, Mackender RO. The effect of tricla-bendazole (“Fasinex”) on protein synthesis by the liver fluke, Fasciola hepatica. Int J Parasitol 1995; 25:421–429

    Article  PubMed  CAS  Google Scholar 

  166. Holmes SD, Fairweather I. Fasciola hepatica: motility responses to metabolic inhibitors in vitro. Exp Parasitol 1985; 59:275–289

    Article  PubMed  CAS  Google Scholar 

  167. Coles GC, Briscoe MG. Benzimidazoles and fluke eggs. Vet Rec 1978; 103:360–361

    PubMed  CAS  Google Scholar 

  168. Coles GC, Simpkin KG. The resistance of nematode eggs to the ovi-cidal activity of benzimidazoles. Res Vet Sci 1977; 22:386–387

    PubMed  CAS  Google Scholar 

  169. Robinson MW, Hoey EM, Fairweather I, Dalton JP, McGonigle S, Trudgett A. Characterisation of a beta-tubulin gene from the liver fluke, Fasciola hepatica. Int J Parasitol 2001; 31:264–268

    Article  Google Scholar 

  170. Schulman MD, Valentino D. Fasciola hepatica: effect of 4- amino-6-trichloroethenyl-1, 3-benzenedisulphonamide on glycolysis in vitro. Exp Parasitol 1980; 49:206–215

    Article  PubMed  CAS  Google Scholar 

  171. Fairweather I, Holmes SD, Threadgold LT. Fasciola hepatica: motility responses to fasciolicides in vitro. Exp Parasitol 1984; 57:209–224

    Article  PubMed  CAS  Google Scholar 

  172. Reinemeyer, C.R., Hutchens, D.E., Eckblad, W.P., Marchiondo, A.A., Shugart, J.I. Dose-confirmation studies of the cestodicidal activity of pyrantel pamoate paste in horses. Vet Parasitol 2006; 138:234–239

    Article  PubMed  CAS  Google Scholar 

  173. Yue C, Lawrence S, Coles GC. Changing behaviour in the common horse tapeworm. Vet Rec 2003; 153:663–664

    PubMed  Google Scholar 

  174. Southworth J, Harvey C, Larson S. Use of praziquantel for the control of Moniezia expansa in lambs. N Z Vet J 1996; 44:112–115

    PubMed  CAS  Google Scholar 

  175. Kwa MSG, Veenstra JG, Roos MH. Benzimidazole resistance in Haemonchus contortus is correlated with a conserved mutation at amino acid 200 in beta -tubulin isotype 1. Mol Biochem Parasitol 1994; 63:299–303

    Article  PubMed  CAS  Google Scholar 

  176. Morris DL, Taylor DH. Echinococcus granulosus: development of resistance to albendazole in an animal model. J Helminthol 1990; 164:171–174

    Article  Google Scholar 

  177. Sarti E, Schantz PM, Avila G, Ambrosio J, Medina-Santillan R, Flisser A. Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study. Trans R Soc Trop Med Hyg 2000; 94:85–89

    Article  PubMed  CAS  Google Scholar 

  178. Allan JC, Velasquez-Tohom M, Fletes C, Torres-Alvarez R, Lopez-Virula G, Yurrita P, Soto de Alfero H, Rivera A, Garcia-Noval J. Mass chemotherapy for intestinal Taenia solium infection. Trans R Soc Trop Med Hyg 1997; 91:595–598

    Article  PubMed  CAS  Google Scholar 

  179. Gonzalez AE, Falcon N, Gavidia C, Garvia HH, Tsang VC, Bernal T, Romero M, Gilman RH. Time-response curve of oxfen-dazole in the treatment of swine cysticercosis. Am J Trop Med Hyg 1998; 59:832–836

    PubMed  CAS  Google Scholar 

  180. Gonzalez AER, Falcon N, Gavidia C, Garcia HH, Tsang VC, Bernal T, Romero M, Gilman RH. Treatment of porcine cyticer-cosis with oxfendazole: a dose-response trial. Vet Rec 1997; 141:420–422

    PubMed  CAS  Google Scholar 

  181. Mohamed AE, Yasawy MI, Al Karawi MA. Combined albenda-zole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology 1998; 45:1690–1694

    PubMed  CAS  Google Scholar 

  182. Ayles HM, Corbett EL, Taylor I, Cowie AG, Bligh J, Walmsley K, Bryceson AD. A combined medical and surgical approach to hydatid disease: 12 years' experience at the Hospital for Tropical Diseases. Ann R Coll Surg Engl 2002; 84:100–105

    PubMed  CAS  Google Scholar 

  183. El-On J. Benzimidazole treatment of cystic echinococcis. Acta Trop 2003; 85:243–252

    Article  PubMed  CAS  Google Scholar 

  184. Bekhti A, Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid disease. Br J Clin Pharmacol 1987; 24:390–392

    PubMed  CAS  Google Scholar 

  185. Wen H, Zhang HW, Muhmut M, Zou PF, New RR, Craig PS. Initial observation on albendazole in combination with cimetidine for the treatment of human cystic echinococcosis. Ann Trop Med Parasitol 1994; 88:49–52

    PubMed  CAS  Google Scholar 

  186. Keshmiri M, Baharvahdat H, Fattahi SH, Davachi B, Dabiri RH, Baradaran H, Rajabzadeh F. Albendazole versus placebo in treatment of echinococcosis. Trans R Soc Trop Med Hyg 2001; 95:190–194

    Article  PubMed  CAS  Google Scholar 

  187. Chai JJ, Menghebat WJ, Sun DY, Bin L, Shi JC, Fu C, Li X, Mao YD, Wang X, Dolikun, Guliber, Wang YC, Gao FH, Xiao S. Observations on clinical efficacy of albendazole emulsion in 264 cases of hepatic cystic echinococcosis. Parasitol Int 2004; 53:3–10

    Article  PubMed  CAS  Google Scholar 

  188. Reuter S, Jensen B, Buttenschoen K, Wolfgang K, Kern P. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicro Chemother 2000; 46:451–456

    Article  CAS  Google Scholar 

  189. Stettler M, Rossignol FR, Fink R, Walker M, Gottstein B, Merli M, Theurillat R, Thormann W, Dricot E, Segers R, Hempill A. Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol 2004; 34:615–624

    Article  PubMed  CAS  Google Scholar 

  190. N'Goran EK, Gnaka HN, Tanner M, Utzinger J. Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among school children from Côte d'Ivoire. Ann Trop Med Parasitol 2003; 97:37–51

    Article  PubMed  CAS  Google Scholar 

  191. Utzinger J, Keiser J, Shuhua Z, Tanner M, Singer BH. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 2003; 47:1487–1495

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

KF and the work reported here on estimation of PZQ ED50s of S. mansoni isolates was financially supported by the INCO-II Programme of the European Commission (contract ICA4-CT-2001-10079). All the authors are members of a European Commission (INCO-DC) Concerted Action on ‘The pattern of praziquantel usage and monitoring of possible resistance in Africa’. The authors are grateful to members of the Concerted Action and other colleagues for continuing helpful discussion and advice.

Author information

Authors and Affiliations

  1. School of Biology, University of Nottingham, University Park, Nottingham, UK

    Michael J. Doenhoff

  2. Department of Clinical Veterinary Science, University of Bristol, Bristol, UK

    Gerald C. Coles

  3. Institute of Cell Biology, Monterotondo, Rome, Italy

    Livia Pica-Mattoccia

  4. School of Biological Sciences, University of Wales Bangor, Bangor, Gwynedd, UK

    Katherine Wheatcroft-Francklow

Authors
  1. Michael J. Doenhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerald C. Coles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Livia Pica-Mattoccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katherine Wheatcroft-Francklow
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Executive Vice President & Chief Medical Offi cer, Idenix Pharmaceuticals, Cambridge, MA, USA

    Douglas L. Mayers MD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Doenhoff, M.J., Coles, G.C., Pica-Mattoccia, L., Wheatcroft-Francklow, K. (2009). Chemotherapy and Drug Resistance in Schistosomiasis,Fascioliasis and Tapeworm Infections. In: Mayers, D.L. (eds) Antimicrobial Drug Resistance. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-59745-180-2_45

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-180-2_45

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-592-7

  • Online ISBN: 978-1-59745-180-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation